MedTrace Logo

Liquid Biopsy and Machine Learning for Early Colorectal Cancer, Adenomas, Lynch Cancers, and Residual Disease Detection

NCT07450612 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1200

Last updated 2026-03-04

No results posted yet for this study

Summary

This is an multicenter study that will test the diagnostic accuracy of a blood test (i.e., a liquid biopsy) for the diagnosis of colorectal cancer (CRC), advanced adenomas (AAs), as well as Lynch-syndrome associated cancers. Additionally, a pre-planned analysis will evaluate the use of this liquid biopsy as a tool for molecular residual disease monitoring purposes.

Conditions

  • Colorectal Cancer
  • Adenoma Colon
  • Adenoma Colon Polyp
  • Colon Adenoma
  • Colo-rectal Cancer
  • Colon Disease
  • Colon Neoplasm
  • Lynch Syndrome
  • Lynch Syndrome I
  • Lynch Syndrome II
  • Lynch Syndrome I (Site-specific Colonic Cancer)
  • LYN Gene Mutation
  • Mismatch Repair Deficiency
  • Mismatch Repair Gene Mutation
  • MLH1 Gene Mutation
  • MSH2 Gene Mutation
  • MSH6 Gene Mutation
  • PMS2 Gene Mutation
  • EPCAM Gene Mutation

Interventions

DIAGNOSTIC_TEST

BEACON

A panel of circulating microRNA, whose expression level is tested in cell-free and exosome-derived samples

Sponsors & Collaborators

  • San Raffaele University

    lead OTHER

Principal Investigators

  • Giulia Martina Cavestro, MD, PhD · IRCCS San Raffaele Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2031-01-15
Completion
2031-08-15

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07450612 on ClinicalTrials.gov